Scientists probe whether anesthesia drug reaches unborn babies
NCT ID NCT06634355
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses donated placentas from healthy pregnancies to measure how much sugammadex, a drug used to reverse anesthesia, passes from mother to baby. Researchers will test drug levels in both the maternal and fetal sides of the placenta in a lab model. The goal is to provide critical safety data for pregnant women needing this medication. Sixteen placentas will be studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 16 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 45 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * informed consent signed * (placenta of a) pregnant women with an uncomplicated pregnancy and delivery Exclusion Criteria: * chronic medication use during pregnancy * maternal diseases during pregnancy (including diabetes mellitus, hypertension, thyroid dysfunction), or any infection (chorioamnionitis and toxoplasmosis, other, rubella, cytomegalovirus, herpes infections, or a positive anti-HIV, anti-hepatitis B virus, or anti-hepatitis C virus serology)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pregnancy are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UZ Leuven
Leuven, Vlaams-Brabant, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does a Mother's weight change the chemistry of her breast milk?
- Can a simple blood test reliably screen for fetal genetic conditions?
- Can a smart insulin pump tailored for pregnancy protect mothers and babies?
- Could more doula visits ease postpartum depression?
- A pen and paper test: does journaling deepen the Mother-Baby bond?
- Could laughter be the key to a calmer, clearer pregnancy?